Kbc Group Nv Cerevel Therapeutics Holdings, Inc. Transaction History

Kbc Group Nv

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 17, 2024	BUY	$38.96 - $42.75 $22,168 - $24,324	569 Added 36.83%	2,114 $86,000
Q1 2024 May 08, 2024	SELL	$40.88 - $43.27 $21,380 - $22,630	-523 Reduced 25.29%	1,545 $65,000
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $41,918 - $87,765	2,068 New	2,068 $88,000
Q3 2023 Feb 15, 2024	SELL	$20.26 - $31.91 $19,307 - $30,410	-953 Reduced 46.08%	1,115 $24,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.